Price T Rowe Associates Inc. MD increased its holdings in Savara Inc (NASDAQ:SVRA – Free Report) by 15.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,692 shares of the company’s stock after acquiring an additional 4,625 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Savara were worth $168,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC increased its stake in Savara by 0.3% in the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after buying an additional 26,613 shares in the last quarter. Vanguard Group Inc. increased its stake in Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares in the last quarter. Vivo Capital LLC increased its stake in Savara by 9.1% in the fourth quarter. Vivo Capital LLC now owns 2,088,323 shares of the company’s stock valued at $9,815,000 after buying an additional 174,974 shares in the last quarter. Wellington Management Group LLP acquired a new position in Savara during the fourth quarter valued at approximately $9,683,000. Finally, Superstring Capital Management LP acquired a new position in Savara during the fourth quarter valued at approximately $3,827,000. Institutional investors and hedge funds own 87.93% of the company’s shares.
Savara price development
SVRA opened at $4.35 on Friday. Savara Inc has a one year low of $3.12 and a one year high of $5.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. The company’s 50 day moving average is $4.30 and its 200 day moving average is $4.60. The stock has a market cap of $601.12 million, a P/E ratio of -11.76 and a beta of 1.00.
Savara (NASDAQ:SVRA – Free Report) last released its quarterly earnings results on Monday, August 12. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.01. Sell-side analysts expect that Savara Inc. will report earnings per share of -$0.41 for the current fiscal year.
Wall Street analysts predict growth
SVRA has been the subject of several research analyst reports. Evercore ISI lowered their price target on shares of Savara from $10.00 to $7.00 and gave the stock an “outperform” rating in a research note on Thursday, May 16. Oppenheimer increased their price target on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26. JMP Securities lowered their price target on shares of Savara from $10.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 13. HC Wainwright reiterated a “buy” rating and gave the stock a $10.00 price target in a research note on Wednesday. Finally, Guggenheim raised their price target on Savara shares from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27. Six equities analysts have rated the stock with a “buy” rating. The company has a consensus rating of “Buy” and a consensus price target of $11.17, according to MarketBeat.com.
Read our latest stock analysis on SVRA
Savara Profile
(Free report)
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The company is focused on developing and commercializing novel therapies to treat patients with rare respiratory diseases. Its products include AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin that the company is developing to treat chronic, methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients.
Selected articles
Get daily news and reviews for Savara – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Savara and related companies with MarketBeat.com’s FREE daily email newsletter.
